Saturday 17 October 2026
Export CRL’s income statement to Excel — free account
Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
299.77
6.47
−2.11%
Follow CRL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.72 | 2.10 | 2.46 | 1.91 | |
P/FCF ratio |
29.39 | 21.58 | 19.07 | 14.16 | |
P/Operating CF |
60.60 | 205.57 | 67.02 | 36.01 | |
P/B ratio |
3.83 | 2.87 | 3.12 | 2.26 | |
Price to Tangible BV |
0.00 | 0.00 | 150.53 | 0.00 | |
EV/Sales |
3.33 | 2.71 | 2.94 | 2.41 | |
EV/EBITDA |
24.09 | 18.65 | 19.90 | 12.36 | |
EV/Operating CF |
22.88 | 17.99 | 16.01 | 12.92 | |
EV/FCF |
35.94 | 27.90 | 22.78 | 17.81 | |
Quick Ratio |
0.80 | 0.82 | 0.82 | 0.84 | |
Current Ratio |
1.35 | 1.36 | 1.29 | 1.37 | |
Net Debt/EBITDA |
12.97 | 13.21 | (47.87) | 9.04 | |
Debt/Assets |
34.78% | 34.45% | 29.94% | 29.09% | |
Debt/Equity |
0.92 | 0.90 | 0.67 | 0.64 | |
Asset Turnover |
0.53 | 0.53 | 0.55 | 0.52 | |
Operating CF/Net income |
(121.27) | (2.77) | (0.53) | 3.93 | |
Capex/Depreciation |
(0.46) | (0.83) | (0.37) | (0.42) | |
Interest Coverage |
3.95 | 4.48 | (11.92) | 5.27 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
22.80% | 16.01% | 19.73% | 17.67% | |
Intangible Assets out of Total Assets |
0.44 | 0.43 | 0.44 | 0.46 | |
Share Based Compensation of Revenue |
1.97% | 2.25% | 1.77% | 2.32% | |
Graham Net Nets |
(0.29) | (0.39) | (0.25) | (0.33) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.13%) | (2.17%) | (1.48%) | (0.99%) | |
Free Cash Flow Yield |
3.40% | 4.63% | 5.24% | 7.06% | |
Revenue per Share |
20.91 | 20.34 | 20.06 | 20.42 | |
Operating CF per Share |
3.74 | 0.84 | 2.98 | 4.34 | |
Capex per Share |
(0.65) | (1.14) | (1.79) | (0.72) | |
Free Cash Flow per Share |
3.09 | (0.30) | 1.18 | 3.62 | |
Cash per Share |
4.00 | 3.92 | 4.31 | 4.21 | |
Shareholders Equity per Share |
59.27 | 60.19 | 63.96 | 69.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
59.27 | 60.19 | 63.96 | 69.30 | |
Free Cash Flow |
148.62 | (14.83) | 58.57 | 178.25 | |
Working Capital |
394.36 | 395.10 | 326.73 | 410.22 | |
Capital Expenditures |
(31.10) | (55.91) | (88.95) | (35.58) | |
Net Current Asset Value |
(3,157.05) | (3,295.09) | (2,518.44) | (2,571.38) | |
EV/EBIT |
147.77 | 155.10 | 469.42 | 68.70 | |
Capex to Sales |
0.03 | 0.06 | 0.09 | 0.04 | |
Price to Operating Income |
120.81 | 119.96 | 392.93 | 54.64 | |
| Other line items | |||||
Average Receivables |
739.66 | 728.44 | 714.89 | 744.34 | |
Average Payables |
143.39 | 141.64 | 144.57 | 152.79 | |
Average Inventory |
312.91 | 324.94 | 288.82 | 319.38 | |
Average Assets |
7,546.35 | 7,656.34 | 7,331.88 | 7,758.83 | |
Average Common Equity |
3,102.81 | 3,073.27 | 3,318.44 | 3,598.73 |
Columns are period end dates